Plant Name: Murraya paniculata
Taxonomic Information:
Plant ID: NPO2715
Plant Latin Name: Murraya paniculata
Taxonomy Genus: Murraya
Taxonomy Family: Rutaceae
Plant External Links:
NCBI TaxonomyDB:
43711
Plant-of-the-World-Online:
774441-1
Used in Medicines:
Country/Region:
Thailand; Indonesia; China; IndiaTraditional Medicine System:
TCM; Ayurveda; SiddhaGeographical Distribution:
United States; Australia; Bangladesh; Cuba; Philippines; Indonesia; India; Mexico; Cambodia; Mauritius; Trinidad and Tobago; Seychelles; China; Vanuatu; Thailand; Dominican Republic; Venezuela; Haiti
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRB3; ADRA2C; ADRA2A; ADRA2B; DRD1; DRD2; GPR35; | |
| TSHR; NPSR1; | |
| RECQL; ALPL; TDP1; BLM; ALOX12; HPGD; AKR1B1; HSD17B2; HSD17B10; NOX4; APEX1; AOX1; POLB; | |
| ACHE; | |
| TEK; INSR; MET; AXL; CSNK2A1; FLT3; CDK1; EGFR; PIM1; SRC; KDR; IGF1R; AURKB; NUAK1; | |
| CA12; CA9; CA7; CA4; | |
| ESR2; ESR1; | |
| THRB; | |
| ESRRB; ESRRA; | |
| TYR; ALDH2; | |
| KDM4E; | |
| MMP9; MMP1; MMP2; | |
| AHR; NFKB1; | |
| FUT7; | |
| ABCB1; | |
| SLC22A6; | |
| LMNA; SMAD3; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | ADRB3 | Beta-3 adrenergic receptor | P13945 | CHEMBL246 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | Unclassified; | GO:0004872; receptor activity | 7.231E-11 | 5.429E-08 | ADRA2A, ADRA2B, ADRA2C, ADRB3, AHR, AXL, DRD1, DRD2, EGFR, ESR1, ESR2, ESRRA, ESRRB, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, TEK, THRB, TSHR |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.824E-09 | 6.968E-07 | ALPL, APEX1, BLM, CYP1A1, CYP1B1, DRD1, EGFR, ESR1, FLT3, NFKB1, NOX4, SRC |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.148E-09 | 7.928E-07 | AKR1B1, ALOX12, AURKB, AXL, CDK1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, LMNA, MMP9, NFKB1, PIM1, SMAD3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 5.500E-09 | 1.641E-06 | ADRA2A, ADRA2B, ADRA2C, ADRB3, DRD2 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 8.091E-09 | 2.288E-06 | ADRA2A, ADRA2B, ADRA2C, ADRB3 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.426E-09 | 2.352E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2D6, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.415E-08 | 5.370E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.637E-08 | 7.543E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 9.519E-08 | 1.727E-05 | ADRA2A, ADRA2B, ADRA2C, INSR, SRC |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.257E-07 | 2.139E-05 | AHR, ESR1, ESR2, ESRRA, ESRRB, PIM1, SRC, THRB |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.451E-07 | 2.376E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.451E-07 | 2.376E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.550E-07 | 2.464E-05 | CA12, CA4, CA7, CA9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.008E-07 | 3.124E-05 | ADRA2A, CA4, CA9, EGFR, HPGD, SLC22A6, TEK, TSHR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.407E-07 | 3.639E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2D6, NOX4, SRC |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.050E-07 | 5.726E-05 | BLM, CA12, CA4, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, MMP1, MMP2, MMP9, SMAD3, THRB |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.074E-07 | 6.905E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.694E-07 | 8.788E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.222E-07 | 9.250E-05 | CYP1A2, CYP2C9, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 7.728E-07 | 9.615E-05 | AXL, EGFR, INSR, MET, NOX4, SRC, TEK |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.854E-07 | 1.160E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2D6 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.091E-06 | 1.251E-04 | ALOX12, AOX1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.117E-06 | 1.264E-04 | ABCB1, AURKB, AXL, BLM, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.718E-06 | 1.802E-04 | AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2D6, ESR1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.898E-06 | 1.968E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.995E-06 | 2.030E-04 | ACHE, ADRA2A, ADRA2C, ADRB3, AOX1, BLM, DRD2, FLT3, HPGD, NFKB1, SLC22A6, SMAD3, TYR |
| MF | Unclassified; | GO:0032403; protein complex binding | 1.995E-06 | 2.030E-04 | ACHE, ADRA2A, APEX1, EGFR, ESRRB, FLT3, IGF1R, INSR, KDR, MMP9, SMAD3, SRC, TSHR |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 2.012E-06 | 2.038E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.446E-06 | 2.432E-04 | CYP1A1, DRD2, LMNA, MMP2, NOX4, SMAD3, SRC, TEK |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.753E-06 | 2.676E-04 | ADRA2A, ADRA2B, ADRA2C, ADRB3, AXL, DRD1, DRD2, FLT3, GPR35, IGF1R, INSR, KDR, MET, NPSR1, SLC22A6, TEK, TSHR |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 2.819E-06 | 2.704E-04 | ADRA2A, ADRA2B, CDK1, EGFR, FLT3, INSR, NOX4, SRC |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 3.011E-06 | 2.864E-04 | EGFR, INSR, KDR |
| BP | GO:0009987; cellular process | GO:0045744; negative regulation of G-protein coupled receptor protein signaling pathway | 3.431E-06 | 3.209E-04 | ADRA2A, ADRB3, DRD2, MET |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 4.938E-06 | 4.461E-04 | ESR1, ESR2, ESRRA, ESRRB, SRC, THRB |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 5.669E-06 | 4.998E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.343E-06 | 5.438E-04 | CA12, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.830E-06 | 6.527E-04 | CYP1A2, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 9.834E-06 | 8.020E-04 | ACHE, EGFR, IGF1R, INSR, THRB |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.115E-05 | 8.912E-04 | APEX1, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.115E-05 | 8.912E-04 | ESR1, ESR2 |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.208E-05 | 9.567E-04 | ADRA2A, ADRB3, AHR, EGFR, IGF1R, INSR, SMAD3, TSHR |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.233E-05 | 9.731E-04 | ADRB3, APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.433E-05 | 1.118E-03 | CA12, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.622E-05 | 1.253E-03 | CDK1, ESR1, ESR2, ESRRA, ESRRB, THRB |
| BP | GO:0040007; growth | GO:0045927; positive regulation of growth | 2.333E-05 | 1.728E-03 | ALOX12, CDK1, CSNK2A1, DRD2, EGFR, INSR, PIM1 |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 2.863E-05 | 2.070E-03 | ADRA2A, ADRA2C, ADRB3 |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 3.057E-05 | 2.176E-03 | ACHE, CDK1, CYP1A1, DRD2, EGFR, SMAD3 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 3.149E-05 | 2.219E-03 | AKR1B1, ALDH2, AOX1, CYP1A2, NOX4 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.440E-05 | 2.378E-03 | ADRA2A, ADRA2B, ADRA2C, AXL, SRC |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 3.501E-05 | 2.405E-03 | CDK1, EGFR, IGF1R, INSR |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 3.956E-05 | 2.675E-03 | ALPL, AXL, CYP1A1, CYP1A2, HPGD, NFKB1, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 4.083E-05 | 2.721E-03 | ALPL, EGFR, MMP2, MMP9, TEK |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 4.087E-05 | 2.721E-03 | ADRA2A, ADRA2C, AHR, AXL, DRD2, EGFR, NFKB1, SMAD3, TYR |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 4.634E-05 | 3.021E-03 | AHR, AXL, CSNK2A1, DRD2, EGFR, ESR1, SRC |
| BP | Unclassified; | GO:0019229; regulation of vasoconstriction | 4.943E-05 | 3.181E-03 | ADRA2A, ADRA2B, ADRA2C, EGFR |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 5.223E-05 | 3.335E-03 | DRD2, EGFR, KDR, NOX4, SRC, TEK |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 5.351E-05 | 3.387E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0030520; intracellular estrogen receptor signaling pathway | 5.351E-05 | 3.387E-03 | ESR1, ESR2, SRC |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 6.103E-05 | 3.808E-03 | CYP1A2, EGFR, ESR1, ESRRA, HPGD |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.138E-05 | 3.819E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032501; multicellular organismal process | GO:0010634; positive regulation of epithelial cell migration | 6.341E-05 | 3.934E-03 | KDR, MET, MMP9, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.661E-05 | 4.054E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 6.661E-05 | 4.054E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.661E-05 | 4.054E-03 | CYP1A2, CYP2C9 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 7.060E-05 | 4.259E-03 | CA7, DRD1, DRD2, KDR, NPSR1, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 7.640E-05 | 4.545E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 8.248E-05 | 4.841E-03 | AURKB, BLM, DRD1, DRD2, EGFR, NOX4, POLB, TYR |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.108E-04 | 6.265E-03 | DRD1, DRD2 |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.108E-04 | 6.265E-03 | BLM, RECQL |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 1.108E-04 | 6.265E-03 | ADRA2A, ADRB3 |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.248E-04 | 6.921E-03 | AXL, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.384E-04 | 7.514E-03 | FLT3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.528E-04 | 8.197E-03 | CYP1A2, EGFR, MMP9 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 1.528E-04 | 8.197E-03 | ADRB3, DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.658E-04 | 8.784E-03 | ALOX12, HPGD |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 1.677E-04 | 8.806E-03 | ALPL, CYP1A1, EGFR, TYR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.682E-04 | 8.806E-03 | AHR, CSNK2A1, KDR |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.731E-04 | 9.016E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 4.165E-09 | 6.997E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.233E-08 | 2.716E-06 | SRC, MMP2, ESR1, MMP9, EGFR, ESR2, HSPA1A |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.868E-07 | 7.241E-06 | ALDH2, CYP1A2, CYP1A1, AOX1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.017E-07 | 7.241E-06 | SRC, MMP2, KDR, ESR1, MMP9, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.122E-07 | 7.241E-06 | MMP1, SRC, MMP2, MMP9, EGFR |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.673E-07 | 7.241E-06 | THRB, ADRB3, GPR35, DRD1, ADRA2C, DRD2, ADRA2B, ADRA2A, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 4.049E-07 | 8.503E-06 | SRC, INSR, KDR, TEK, DRD2, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.867E-07 | 1.095E-05 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.894E-06 | 3.182E-05 | SMAD3, ADRB3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.233E-06 | 7.327E-05 | SMAD3, FLT3, MMP1, MMP2, MET, MMP9, EGFR, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 8.804E-06 | 1.138E-04 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.927E-06 | 5.997E-05 | CYP2C9, CYP2D6, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.342E-07 | 7.241E-06 | CA12, CA4, CA7, CA9 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 9.865E-06 | 1.184E-04 | SRC, CDK1, DRD1, DRD2, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.123E-05 | 2.378E-04 | INSR, TEK, EGFR, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.945E-05 | 4.615E-04 | ABCB1, PIM1, CYP1B1, MMP9, MET, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.600E-05 | 2.730E-04 | HPGD, FLT3, MMP9, MET, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.174E-04 | 8.574E-04 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 7.078E-05 | 5.945E-04 | SRC, MET, EGFR, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 8.854E-05 | 6.761E-04 | SRC, ESR1, NFKB1, ESR2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.778E-05 | 3.734E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 5.927E-05 | 5.241E-04 | CYP2C9, CYP1A2, CYP1A1, AOX1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 2.107E-04 | 1.416E-03 | ADRB3, INSR, ADRA2C, ADRA2B, ADRA2A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 7.495E-05 | 5.996E-04 | CYP2C9, CYP2D6, CYP1A2, AOX1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.275E-04 | 2.116E-03 | SMAD3, MMP2, PIM1, NFKB1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.730E-04 | 3.209E-03 | CYP2C9, FUT7, ALDH2, HSD17B2, CYP1A2, CYP1A1, AKR1B1, ALPL, AOX1, ALOX12, TYR, HSD17B10 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.054E-04 | 3.063E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.469E-04 | 1.028E-03 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 9.245E-04 | 4.707E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.306E-03 | 6.096E-03 | SMAD3, SRC, MMP9, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 8.031E-04 | 4.352E-03 | ADRB3, INSR, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 8.458E-04 | 4.440E-03 | FLT3, PIM1, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.185E-03 | 5.855E-03 | INSR, HSPA1A, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00280 | Valine, leucine and isoleucine degradation | 5.105E-04 | 3.063E-03 | ALDH2, AOX1, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.295E-03 | 6.096E-03 | SMAD3, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.599E-03 | 7.071E-03 | MET, EGFR, IGF1R |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 5.425E-04 | 3.143E-03 | DRD1, DRD2, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.353E-03 | 6.144E-03 | FLT3, MET, EGFR |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADRA2C; ADRB3; DRD2; AKR1B1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DRD2; EGFR; ABCB1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; ESRRA; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| NA: NA | Itching | NA | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | ADRB3; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; ADRB3; DRD1; DRD2; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; MMP2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADRB3; DRD2; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| NA: NA | Hyperaemia | NA | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; ADRB3; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| NA: NA | HIV infections | NA | AHR; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; ADRA2A; ADRA2C; DRD1; DRD2; INSR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; ESRRA; MMP1; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; EGFR; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; SRC; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | ADRB3; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; DRD2; ABCB1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; ADRB3; DRD2; ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; INSR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ADRB3; ESRRA; EGFR; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; DRD2; INSR; EGFR; CA9; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; ALDH2; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; MMP2; |
| NA: NA | False perceptions | NA | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; DRD2; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; MMP2; ABCB1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; SRC; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; ALDH2; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; ABCB1; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; TEK; MMP9; EGFR; SRC; MMP2; ABCB1; CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; AKR1B1; MMP1; TYR; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| NA: NA | Vomiting | NA | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; DRD2; ALDH2; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; INSR; THRB; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; ESRRA; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ADRA2C; DRD2; INSR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; ESRRA; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADRB3; INSR; AKR1B1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | ADRB3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; DRD2; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRB3; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | ADRB3; DRD2; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; ADRB3; DRD1; INSR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; ALPL; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | ADRB3; DRD2; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; CA9; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; TEK; MMP9; EGFR; SRC; MMP2; ABCB1; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
